PURE Bioscience Presents PURE Hard Surface at American Correctional Association’s Annual Congress

SDC-Based Disinfectant and Sanitizer Kills Bacteria and Viruses in 30 Seconds; Effective against MRSA and NDM-1 Positive Bacteria

SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, is exhibiting its PURE™ Hard Surface disinfectant and food contact surface sanitizer at the American Correctional Association (ACA) 141st Congress of Correction in Kissimmee, Florida from August 5 – 10. The ACA is the oldest corrections association and represents more than 20,000 active professional members. The ACA’s annual Congress of Correction is the largest gathering of corrections personnel in the U.S.

PURE recently announced a major amendment to its PURE Hard Surface label, which added additional pathogens, including Hepatitis B, Hepatitis C and multiple Carbapenem-resistant bacteria as well as reduced virus kill times to as quickly as 30 seconds. The independent studies supporting the EPA registration show that PURE Hard Surface offers unparalleled efficacy against dangerous and resistant pathogens while remaining an EPA Category IV (least toxic) product. In addition, its odorless and non-flammable formula makes PURE Hard Surface ideal for use in the communal settings of correctional facilities, along with the recently introduced low-foam PURE Commercial Floor Cleaner concentrate made with environmentally preferred surfactants.

“Studies have indicated that transmission prevention in closed settings is difficult, time consuming and expensive,” said Jeff Donnell, Vice President, Business Development, for PURE Bioscience. “We’re excited to present to ACA members the convenience, cost- and life-saving benefits of integrating PURE Hard Surface into both routine and critical cleaning protocols, and appreciate the opportunity to broaden awareness of PURE Hard Surface to federal, state and local corrections professionals and administrators, as well as to corrections healthcare professionals.”

“Our recent EPA registration of expanded claims for PURE Hard Surface elevates it far above the competition as the responsible choice for law enforcement and corrections officials tasked with controlling dangerous outbreaks of Staph and other resistant bacteria throughout institutional populations and among employees,” added Donnell.

PURE Bioscience’s long-term case study with the Tulsa County jail demonstrates the power of its product to control the spread of disease. More than five years have passed since the implementation of PURE’s product into cleaning and maintenance protocols, and outbreaks of Staph and resistant Staph have been eliminated from the Tulsa facility. PURE’s SDC-based disinfectant is also being used by the Palm Beach County Sheriff’s office.

PURE recently exhibited at the 71st Annual National Sheriffs’ Association Conference and Exhibition in St. Louis, Missouri.

About PURE Hard Surface

U.S. EPA-registered PURE Hard Surface disinfectant and food contact surface sanitizer provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial and viral kill times and 24-hour residual protection. PURE Hard Surface completely kills resistant pathogens like MRSA and Carbapenem-resistant Klebsiella pneumoniae (NDM-1) and also effectively eliminates dangerous fungi and viruses including HIV, Hepatitis B, Hepatitis C, Norovirus, Influenza A, Avian Influenza and H1N1 as well as hazardous food pathogens such as E. coli, Salmonella and Campylobacter. PURE Hard Surface delivers powerful broad-spectrum efficacy while remaining classified as least-toxic (Category IV) by the US EPA, and its active ingredient, SDC, has been determined Generally Recognized as Safe (GRAS) for use as a biocide on food processing equipment, machinery and utensils.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.



CONTACT:

PURE Bioscience Investor Contact:
Lippert/Heilshorn & Associates
Don Markley, Senior Vice President
310-691-7100
[email protected]
or
PURE Bioscience Media Contact:
Gutenberg Communications
Michael Gallo, 212-239-8594
[email protected]

KEYWORDS:   United States  North America  California  Florida  Missouri

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Other Health  Manufacturing  Chemicals/Plastics  Environment

MEDIA:

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.